Nurse Leads Clinical Trials for Innovative Cancer Therapies
Several years ago, Melissa Martinez was watching her youngest daughter’s basketball game when a player had a seizure. With no one else knowing how to help, Martinez’s daughter shouted, “My…
Read MoreNurse Leads Clinical Trials for Innovative Cancer Therapies
Over Half of Crohn’s Patients Achieve Remission with Lilly’s Mirikizumab at One Year
Eli Lilly’s Mirikizumab Shows Promise in Phase 3 Study for Crohn’s Disease In Eli Lilly and Company’s pivotal Phase 3 VIVID-1 study, patients with moderately to severely active Crohn’s disease,…
Upneeq® Clinches 2024 Shape Skin Award for ‘Best Lift’ in the Professional Treatment Category
RVL Pharmaceuticals has proudly announced that Upneeq® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, its prescription eye drop, has received the esteemed 2024 Shape Skin Award from Shape Magazine. This prestigious recognition,…
Bluebird Bio Investor Alert: Class Action Lawsuit Deadline Approaching
Kirby McInerney LLP is reminding investors of the upcoming May 28, 2024 deadline to seek lead plaintiff status in a federal securities class action related to bluebird bio, Inc. (NASDAQ:…
Guardant Health Discloses Inducement Awards in Accordance with Nasdaq Listing Rule 5635(c)(4)
Guardant Health, Inc. (Nasdaq: GH), a prominent player in precision oncology, disclosed today that its Compensation Committee, on April 22, 2024, sanctioned the allocation of restricted stock units (“RSUs”) corresponding…
Brenmiller’s Project Pipeline Surges to 49 Projects, Encompassing Over $500 Million Potential Value in 12 Industries Across 13 Countries
The leading developer in thermal energy storage (“TES”) globally, Brenmiller, announced significant expansion in its project pipeline, marking a record level for the Company. As of May 1, 2024, Brenmiller…
MAIA Biotechnology Set to Showcase at the 2024 BIO International Convention
MAIA Biotechnology, Inc. (NYSE American: MAIA), a pioneering company focused on developing immunotherapies targeting telomeres for cancer treatment, has confirmed its participation in the prestigious BIO International Convention scheduled from…
Unraveling ANKTIVA’s Triangle Offense: Exploring with Dr. Patrick Soon-Shiong and Dr. Ashish Kamat on UroToday Podcast
Today, ImmunityBio has announced the release of three podcasts in collaboration with UroToday, shedding light on the recent FDA approval of ANKTIVA® (N-803, also known as nogapendekin alfa inbakicept-pmln) alongside…
NADclinic and Bontac Bio-Engineering Form Strategic Partnership to Advance Global Wellness with NAD+
NADclinic Group and Bontac Bio-Engineering (Shenzhen) Co., Ltd have forged a robust strategic alliance aimed at shaping the future landscape of global health and wellness. Drawing upon their respective proficiencies…
Report on Reproductive Hormones and Proteins Testing Markets: 2015-2024 & 2033
The latest addition to ResearchAndMarkets.com’s offerings is the “Reproductive Hormones and Proteins Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033” report. This insightful analysis delves into…
Marinus Pharmaceuticals Unveils Significant Developments for Tuberous Sclerosis Complex Program
Aiming to advance treatment options for seizure disorders, Marinus Pharmaceuticals has successfully completed enrollment in the global Phase 3 TrustTSC trial. This trial assesses oral ganaxolone’s efficacy in managing seizures…
Azitra, Inc. Reveals Promising Preclinical Results for ATR-04 at Society of Investigative Dermatology Annual Meeting
Azitra, Inc., a clinical-stage biopharmaceutical company dedicated to pioneering innovative therapies for precision dermatology, has unveiled preclinical findings from its cutting-edge platform and pipeline. These findings are being presented at…